Held in conjunction with the Oncology Nursing Society's 42nd Annual Congress
Will be available soon.
This activity has been designed to meet the educational needs of nurses involved in the care of patients living with hematologic cancers.
At the conclusion of this program, participants should be able to:
- Provide an overview of the latest developments in CAR T-cell therapy for patients with relapsed/refractory blood cancer
- Explain the nurse's role in assessment, monitoring for and managing side effects, including CRS and neurotoxicities
- Describe the nurse's role in preparing patients and family members about potential side effects of CART treatment
- Address the need for psychosocial support of the patient and family throughout the treatment process
Angela Kirk, PA-C
Seattle Cancer Care Alliance
Fred Hutchinson Cancer Research Center
Leslie Smith, RN, AOCNS, APRN-CNS
Oncology/Transplant Clinical Nurse Specialist
National Institutes of Health
Megan Harvey, MSN, RN
Clinical Nurse III
Hematology/Bone Marrow Transplant
Hospital of the University of Pennsylvania
Sponsors and Supporters
This activity is supported by educational grants from Kite Pharma and Novartis.